Eupraxia continues to observe positive treatment outcomes in its ongoing Phase 1b/2a trial, including for the first time clinical responses measured 9 months after dosing with EP-104GIAt 9 months active drug continued to be released into the esophagus in patients at a rate similar to what was seen at the 3- and 6-month time points. This is an unprecedented result with an injectable delivery system in patients with EoEAlso, at 9 months patients demonstrated sustained or improved treatment outcomes compared t ...

Aptose is developing TUS+VEN+AZA as a one-of-a-kind safe and mutation agnostic frontline triple drug therapy for newly diagnosed AML patients First two dose cohorts of TUS+VEN+AZA triplet demonstrate safety, complete remissions, and MRD negativity across patients with diverse mutations, including TP53-mutated/CK AML and FLT3-wildtype AML patients SAN DIEGO and TORONTO, May 05, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF), a clinical-stage precision onco ...

WARREN, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in the upcoming Citizens Life Sciences Conference from May 7-8 in New York City. The Aquestive team will hold a fireside chat on May 8th at 10 am ET; management will also be hosting ...

New TransUnion analysis explores the percentage of student loan borrowers at risk of default and the credit score impactsCHICAGO, May 05, 2025 (GLOBE NEWSWIRE) -- As the U.S. Department of Education begins resuming collections activities among defaulted borrowers, new research reveals that the number of consumers at risk for default has soared past pre-pandemic levels. These findings come from a new analysis conducted by TransUnion (NYSE: TRU) and featured at the company’s 2025 Financial Services Summit, at ...

Core Points - Rafael Holdings, Inc. announced revised subscription rights for its rights offering, with a Record Date of May 9, 2025 [1][5] - The rights offering will allow holders to purchase shares of Class B Common Stock at a subscription price of $1.28 per share [3][4] - The subscription period will run from May 13, 2025, to May 29, 2025, unless extended or terminated [5][7] Rights Offering Details - Each holder will receive one non-transferable subscription right for each share held as of the Record Date, allowing the purchase of 0.603 of a share of Class B Common Stock [3] - Subscription rights can only be exercised in whole numbers, and fractional shares will not be issued [3] - Howard Jonas, the Executive Chairman, will enter into a Standby Purchase Agreement to buy any unsubscribed shares at the same price [4] Participation Requirements - Former holders of Cyclo Therapeutics, Inc. must submit their letter of transmittal to Equiniti Trust Company to participate in the rights offering [2] - Holders must complete open market purchases by May 8, 2025, to be considered record holders on the Record Date [1][7] Important Dates - May 8, 2025: Ownership Day for shares and/or Public Warrants [7] - May 9, 2025: Record Date [7] - May 13, 2025: Subscription Period Begins [7] - May 29, 2025: Subscription Period Ends at 5:00 PM ET [5][7] Company Overview - Rafael Holdings, Inc. holds interests in clinical and early-stage pharmaceutical companies, including Cyclo Therapeutics, LLC, which is developing Trappsol Cyclo™ for Niemann-Pick Disease Type C1 [10]

New Drilling Continues to Expand Deposit to South and at DepthMONTREAL, May 05, 2025 (GLOBE NEWSWIRE) -- Osisko Metals Incorporated (the “Company or "Osisko Metals") (TSX-V: OM; OTCQX: OMZNF; FRANKFURT: 0B51) is pleased to announce new drilling results from the 2025 drilling program at the Gaspé Copper Project, located in the Gaspé Peninsula of Eastern Québec. Results for six new holes are reported below, located at the southern end of the deposit defined in the 2024 Mineral Resource Estimate (“MRE”, see at ...

Sequel Pharma Executes Agreement with CDMO for Drug Product ManufacturingMISSISSAUGA, Ontario, May 05, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that its funding and commercialization partner, Sequel Pharma, LLC (“Sequel”), has executed an agreement with a leading international contract development and manufacturing organization (“CDMO”) for production of the formulated and packaged drug (i.e., “Dru ...

Program Aimed at Generating Key Data in Support of the Benefits of CYTOGAM® in the Management of Cytomegalovirus (CMV) in Solid Organ TransplantationA Total of 10 Studies will be Conducted in Collaboration with Leading U.S. Physicians, Primarily as Investigator-Initiated Studies (IIS)Results of the Planned Studies are Expected to be Published and/or Presented in Peer Reviewed Industry Journals and Medical Meetings in the Coming Years REHOVOT, Israel, and HOBOKEN, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Kamad ...

Core Insights - Algorhythm Holdings, Inc. has acquired SemiCab Solutions Private Ltd., enhancing its presence in the rapidly growing Indian logistics market [1][2] - The acquisition provides access to a significant multinational customer base and scalable growth opportunities through SemiCab's AI platform [4][6] Company Overview - Algorhythm Holdings is a diversified technology-driven holding company with a focus on AI technology and consumer electronics [9] - SemiCab is recognized as an emerging leader in the global logistics and distribution industry, utilizing AI to optimize supply chain operations [10] Acquisition Details - Algorhythm's subsidiary, SemiCab Holdings, LLC, acquired 9,999 of the 10,000 equity shares of SemiCab India for a $1.75 million promissory note and 119,742 shares of common stock [2] - This acquisition marks Algorhythm's second transaction with SemiCab, Inc., following the acquisition of its U.S. business in July 2024 [1] Market Context - India's logistics sector, valued at $1.3 trillion, is undergoing modernization, supported by government initiatives like the Gati Shakti National Master Plan [5] - The National Digital Freight Exchange (NDFE) has selected SemiCab as its AI logistics partner, indicating strong institutional support for the company's technology [5] Performance Metrics - SemiCab India has more than doubled its annualized revenue run rate from approximately $1.8 million to approximately $4.5 million since January 2025, with expectations to double again by year-end [6] - The platform improves freight utilization rates from approximately 65% to up to 90% and reduces total shipping costs by up to 10% [7] Strategic Advantages - The acquisition allows Algorhythm to tap into existing contracts with leading FMCG companies in India, providing a pathway to scale operations significantly [6] - SemiCab's AI platform enhances visibility in the transportation network, enabling real-time collaboration between shippers and transporters [8]

FENIX OUTDOOR INTERNATIONAL AGInterim condensed consolidated financial statements for the period ended 31 March 2025 First quarter 2025-01-01 – 2025-03-31 The total income of the Group was TEUR 160,082 (TEUR: 168,676), a decrease of 5.1%.The EBITDA of the Group was TEUR 18,028 (TEUR: 27,212).The operating profit of the Group was TEUR 5,181 (TEUR: 12,782).The profit before tax of the Group was TEUR 3,673 (TEUR: 11,363).The profit after tax of the Group was TEUR 94 (TEUR: 6,910).Earnings per share amounted to ...